ReViral: Funding, Investors & Team (Oct 2026)
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.
ReViral has raised $44.0M across 1 funding round on record, the most recent an undisclosed round of $44.0M announced in Aug 2020.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ReViral Company Profile and Key Stats
Latest funding round on record: Aug 2020.
ReViral Funding Rounds
ReViral Founders and Leadership Team
Contact details for the ReViral team: 1 of 1 has an email address on file.
Start 14-day free trial →ReViral Funding Compared to Other Biotechnology Startups
ReViral's latest round of $44.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ReViral in Biotechnology and Stevenage
Companies Similar to ReViral
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
ReViral Funding FAQs
What does ReViral do?
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.
How much funding has ReViral raised?
ReViral has raised $44.0M across 1 round on record. The most recent is an undisclosed round of $44.0M announced in Aug 2020.
When did ReViral last raise funding?
ReViral's most recent funding round on record is an undisclosed round of $44.0M, announced in Aug 2020.
Who is the CEO of ReViral?
Alex Sapir is listed as CEO at ReViral.
Where is ReViral headquartered?
ReViral is based in Stevenage, Herefordshire, United Kingdom.
How many employees does ReViral have?
ReViral is in the 11-50 employee band.
How does ReViral's funding compare to other Biotechnology startups?
ReViral's latest round of $44.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ReViral Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ReViral is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.